Loss of TRAIL-Receptors Is a Recurrent Feature in Pancreatic Cancer and Determines the Prognosis of Patients with No Nodal Metastasis after Surgery

INTRODUCTION: Agonistic antibodies targeting TRAIL-receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are being developed as a novel therapeutic approach in cancer therapy including pancreatic cancer. However, the cellular distribution of these receptors in primary pancreatic cancer samples has not been suff...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Gallmeier, Eike, Bader, Dominik C., Kriegl, Lydia, Berezowska, Sabina, Seeliger, Hendrik, Göke, Burkhard, Kirchner, Thomas, Bruns, Christiane, De Toni, Enrico N.
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2013
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3584093/
https://ncbi.nlm.nih.gov/pubmed/23460812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0056760
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires